With financial and in-kind support from the Krembil Foundation, Conscience’s Developing Medicines through Open Science (DMOS) program, OICR’s Cancer Therapeutics Innovation Pipeline (CTIP), Charles River Laboratories, Structural Genomics Consortium, Institute of Cancer Research, University of Pennsylvania, Montreal Children’s Hospital/McGill University, CAMH, Children’s Cancer Institute, Sant Joan de Deu Hospital, Reaction Biology, GL Chemtec and The Brain Tumour Charity, M4K Pharma has made critical strides toward realizing an affordable, first-in-class therapy for children affected by DIPG.